CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizumab. Findings from the German Phase III FIRE study were presented at the 2013 meeting of the American Society of Clinical Oncology in Chicago by Professor Volker Heinemann from Munich University. He explained to Peter Goodwin why this research has clarified the clinical decision-making process for patients who have the non-mutated form of the KRAS gene and are thus sensitive to both of these targeted agents.
You may also like...
Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia 6 Aug, 2013 Audio Journal of Oncology in Advance – March 15th, 2008 16 Mar, 2008 Low risk prostate cancer: scope and benefits from reducing overtreatment 24 Mar, 2013 Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time 24 Mar, 2015
- Previous story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
- Next story Heat shock protein inhibitor brings new hope in advanced pre-treated lung cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014